Sign up to save your podcasts
Or
Share Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
Faculty: Christoph U. Correll, MD
Faculty: Jonathan M. Meyer
Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.
View all episodes
By ReachMDFaculty: Christoph U. Correll, MD
Faculty: Jonathan M. Meyer
Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.